Addex Therapeutics(NASDAQ) ADXN

Market Cap$3.68M

Since IPO (2020)-99%

5 Year-98%

1 Year-52%

1 Month-36%

$3.70

+1.37%

+0.05Today

Addex Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 3.70	2026-09-08

Addex Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+1.37%	USD 3.65	2026-09-01
1 month	-36.21%	USD 5.80	2026-08-07
3 month	-43.08%	USD 6.50	2026-06-10
Year to date	-52.07%	USD 7.72	2025-12-31
1 year	-52.26%	USD 7.75	2025-09-08
3 year	-57.95%	USD 8.80	2023-09-08
5 year	-98.12%	USD 196.30	2021-09-09
Since inception	-98.74%	USD 290.00	2020-01-29

Addex Therapeutics Financials at a Glance

Market Cap

$3.68M

Revenue (TTM)

CHF 74.04K

Net Income (TTM)

-CHF 6.97M

EPS (TTM)

-$9.31

P/E Ratio

-0.40

Dividend

$0.00

Beta (Volatility)

0.38 (Low)

Dividend

$0.00

Beta (Volatility)

0.38 (Low)

Price

$3.70

Volume

1,568

Open

$3.65

Price

$3.70

Volume

1,568

Open

$3.65

Previous Close

$3.70

Daily Range

$3.53 - $3.84

52-Week Range

$3.40 - $12.05

Estimated Earnings Date

Aug 24, 2026

Dividend

$0.00

Beta (Volatility)

0.38 (Low)

Price

$3.70

Volume

1,568

Open

$3.65

Previous Close

$3.70

Daily Range

$3.53 - $3.84

52-Week Range

$3.40 - $12.05

Estimated Earnings Date

Aug 24, 2026

ADXN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Addex Therapeutics

Addex Therapeutics Ltd is a biopharmaceutical company based in Switzerland, focused on developing small-molecule drugs for central nervous system (CNS) disorders. The company specializes in discovering and advancing allosteric modulators for G-protein coupled receptors, with key programs targeting conditions such as Parkinson's disease and epilepsy.

Products and Services

Dipraglurant: Investigational treatment for Parkinson's disease levodopa-induced dyskinesia
ADX71149: Developed for epilepsy and other CNS conditions
GABAB PAM: A compound aimed at treating addiction

Growth Outlook

Strong pipeline with multiple investigational drugs in development
Collaborations with major partners like Janssen Pharmaceuticals and Indivior PLC
Focus on CNS disorders presents significant market opportunities

Financial Highlights

Recent quarterly revenue of 7,691 CHF, indicating ongoing development costs
Trailing twelve months (TTM) revenue of 36,375 CHF, reflecting early-stage commercialization
Cash and short-term investments totaled 937,500 CHF as of March 31, 2026

Addex Therapeutics Ltd operates in a highly specialized sector, focusing on innovative treatments for CNS disorders. The company's strategic partnerships and robust pipeline position it well for future growth. Despite current financial challenges, including negative net income and high operating expenses, the potential for breakthrough therapies in a growing market remains significant. Investors may find interest in the company's unique approach to drug development and its commitment to addressing unmet medical needs.

AI Generated • Aug 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

Headquarters

Geneva, GE 1202, CH

ADXN Financials

Key Financial Metrics (TTM)

Gross Margin

84.32%

Operating Margin

-2999.71%

Net Income Margin

-7775.20%

Return on Equity

-131.35%

Return on Capital

-58.62%

Return on Assets

-146.41%

Earnings Yield

-2.50%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.68M

Shares Outstanding

994.30K

Volume

1.57K

Avg. Volume

135.38K

Financials (TTM)

Gross Profit

-CHF 196.55K

Operating Income

-CHF 2.69M

EBITDA

-CHF 7.06M

Operating Cash Flow

-CHF 2.33M

Capital Expenditure

CHF 0.00

Free Cash Flow

-CHF 2.33M

Cash & ST Invst.

CHF 937.50K

Total Debt

CHF 102.27K

Addex Therapeutics Performance Analysis

Addex Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	-18.3%
Q4	2025-12-31	-99.2%
Q1	2026-03-31	3001.2%

Addex Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-33.3%
Q3	2025-09-30	30.5%
Q4	2025-12-31	7.9%
Q1	2026-03-31	21.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

CHF 7.69K

N/A

Gross Profit

-CHF 28.44K

N/A

Gross Margin

-3.70%

N/A

Market Cap

$3.68M

N/A

Market Cap/Employee

$1.23M

N/A

Employees

N/A

Net Income

-CHF 1.71M

-16.2%

EBITDA

-CHF 1.70M

-15.7%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

CHF 937.50K

-66.9%

Total Debt

CHF 102.27K

+154.4%

Accounts Receivable

CHF 31.99K

-9.5%

Inventory

CHF 0.00

N/A

Long Term Debt

CHF 25.03K

-23.7%

Short Term Debt

CHF 77.24K

+944.1%

Return on Assets

-1.46%

N/A

Return on Invested Capital

-76.01%

N/A

Free Cash Flow

-CHF 765.84K

-27.9%

Operating Cash Flow

-CHF 765.84K

-27.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

TCRTAlaunos Therapeutics, Inc.

TCRTAlaunos Therapeutics, Inc.$1.57-3.68%

RADXRadiopharm Theranostics Limited

RADXRadiopharm Theranostics Limited$2.12+1.92%

CDIOCardio Diagnostics Holdings, Inc.

CDIOCardio Diagnostics Holdings, Inc.$1.96+5.38%

ADILAdial Pharmaceuticals, Inc.

ADILAdial Pharmaceuticals, Inc.$6.65-6.60%

BCLIBrainstorm Cell Therapeutics Inc.

BCLIBrainstorm Cell Therapeutics Inc.$0.99-5.71%

QNRXQuoin Pharmaceuticals, Ltd.

QNRXQuoin Pharmaceuticals, Ltd.$7.15-1.52%

NRSNNeuroSense Therapeutics Ltd.

NRSNNeuroSense Therapeutics Ltd.$0.42-18.15%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$10.65+0.06%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$44.08-0.05%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$123.27+0.05%

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF$18.72+0.01%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$44.39-0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$72.16-0.00%

INTCIntel

INTCIntel$104.47+0.09%

Questions About ADXN

What is the current price of Addex Therapeutics?

Addex Therapeutics is trading at $3.70 per share.

What is the 52-week range for Addex Therapeutics?

Over the past 52 weeks, Addex Therapeutics has traded between $3.40 and $12.05.

How much debt does Addex Therapeutics have?

Addex Therapeutics total debt is unavailable.

How much cash does Addex Therapeutics have on hand?

Addex Therapeutics does not have cash on hand data available.

What is Addex Therapeutics’s dividend yield?

Addex Therapeutics does not currently have a dividend yield.

Addex Therapeutics(NASDAQ) ADXN

Addex Therapeutics Financials at a Glance

ADXN News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Addex Therapeutics

ADXN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Addex Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ADXN

What is the current price of Addex Therapeutics?

What is the 52-week range for Addex Therapeutics?

How much debt does Addex Therapeutics have?

How much cash does Addex Therapeutics have on hand?

What is Addex Therapeutics’s dividend yield?

Premium Investing Services